natgillin/translations-raw huggingface dataset:
Der blev ikke observeret tydelige bivirkninger på hundyrs forplantningsorganer i generelle toksikologiforsøg hos rotter og aber. 
No apparent adverse effects on female reproductive organs were observed in general toxicology studies in rats and monkeys.
Mikrokerneinduktionsmekanismen var unormal kromosomsegregering (aneugenicitet) og ikke en klastogen virkning på kromosomerne. 
The mechanism of micronucleus induction was abnormal chromosome segregation (aneugenicity) and not a clastogenic effect on chromosomes.
Grad 4-hypertension (livstruende konsekvenser, akut behandling indiceret) 
Grade 4 hypertension (life threatening consequences, urgent intervention indicated)
Pakning til behandlingsopstart 
Treatment initiation pack
Tabel 4: Effektresultater i ALTA (ITT-population) Effektparameter 
Table 4: Efficacy results in ALTA (ITT population) Efficacy parameter
IRC-bedømmelse af intrakraniel ORR og varighed af intrakranielt respons hos patienter i ALTA med målbare hjernemetastaser (længste diameter ≥ 10 mm) ved baseline er opsummeret i tabel 5. 
IRC assessments of intracranial ORR and duration of intracranial response in patients from ALTA with measurable brain metastases (≥ 10 mm in longest diameter) at baseline are summarised in Table 5.
Uændret brigatinib repræsenterede henholdsvis 41 % og 86 % af den totale radioaktivitet i fæces og urin, og resten var metabolitter. 
Unchanged brigatinib represented 41% and 86% of the total radioactivity in faeces and urine, respectively, the remainder being metabolites.
FREMSTILLERE ANSVARLIG FOR BATCHFRIGIVELSE 
MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
Testikeltoksicitet blev observeret i dyreforsøg med gentagne doser. 
Testicular toxicity was observed in repeat-dose animal studies.
Uændret brigatinib var den største cirkulerende radioaktive komponent (92 %) sammen med AP26123 (3,5 %), som er den primære metabolit, der også er observeret in vitro. 
Unchanged brigatinib was the major circulating radioactive component (92%) along with AP26123 (3.5%), the primary metabolite also observed in vitro.
Bivirkninger† alle grader 
Adverse reactions† all grades
Høj alder og kortere intervaller (under 7 dage) mellem den sidst indtagede dosis crizotinib og første indtagede dosis Alunbrig blev uafhængigt af hinanden forbundet med en øget forekomst af disse pulmonale bivirkninger. 
Increased age and shorter interval (less than 7 days) between the last dose of crizotinib and the first dose of Alunbrig were independently associated with an increased rate of these pulmonary adverse reactions.
• Hvis du kaster op efter at have taget Alunbrig, må du ikke tage flere tabletter, før det er tid til den næste planlagte dosis. 
• If you vomit after taking Alunbrig, do not take any more tablets until your next scheduled dose.
• Aktivt stof: brigatinib. 
• The active substance is brigatinib.
Af disse blev der rapporteret tre Grad 3-bivirkninger (2,7 %), herunder maculaødem og katarakt. 
Of these, three Grade 3 adverse reactions (2.7%) including macular oedema and cataract were reported.
Alunbrig frarådes under graviditeten, medmindre fordelene opvejer risikoen for barnet. 
Alunbrig is not recommended during pregnancy unless the benefit outweighs the risk to the baby.
• betændelse i munden og på læberne (stomatit) 
• inflammation of the mouth and lips (stomatitis)
Hvis Alunbrig anvendes under graviditeten, eller hvis patienten bliver gravid, under behandling med dette lægemiddel, skal patienten informeres om den potentielle risiko for et foster. 
If Alunbrig is used during pregnancy, or if the patient becomes pregnant while taking this medicinal product, the patient should be apprised of the potential hazard to a foetus.
Intrakraniel sygdomskontrolrate 
Intracranial disease control rate
Mediantiden til debut for forhøjet amylase og lipase var henholdsvis 17 dage og 29 dage. 
The median time to onset for amylase elevations and lipase elevations was 17 days and 29 days, respectively.
Forhøjet lipase eller amylase 
Elevation of lipase or amylase
Virkningen af gemfibrozil på farmakokinetikken for brigatinib er ikke klinisk betydningsfuld, og den underliggende mekanisme for reduceret eksponering for brigatinib er ukendt. 
The effect of gemfibrozil on the pharmacokinetics of brigatinib is not clinically meaningful and the underlying mechanism for the decreased exposure of brigatinib is unknown.
De er hvælvede på over- og undersiden. 
They are convex on the upper and lower side.
Hold ikke op med at tage Alunbrig uden at tale med lægen. 
Do not stop taking Alunbrig before talking to your doctor.
I ALTA fik 69 % af patienterne hyperglykæmi. 
In ALTA, 69% of patients experienced hyperglycaemia.
Tag den næste dosis på det næste planlagte tidspunkt. 
Take your next dose at your regular time.
Der foreligger ingen humane data om Alunbrigs virkning på fertilitet. 
No human data on the effect of Alunbrig on fertility are available.
Alunbrig filmovertrukne tabletter er hvide til offwhite og ovale (90 mg og 180 mg) eller runde (30 mg). 
Alunbrig film-coated tablets are white to off-white, oval (90 mg and 180 mg) or round (30 mg).
Status for ALK-positiv NSCLC skal være kendt, inden indledning af behandling med Alunbrig. 
ALK-positive NSCLC status should be known prior to initiation of Alunbrig therapy.
Ingen patienter fik dosisreduktion som følge af hyperglykæmi. 
No patients had dose reductions due to hyperglycaemia.
Hvis du er gravid, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge din læge til råds om risikoen ved at tage Alunbrig under graviditeten. 
If you are pregnant or think you may be pregnant or are planning to have a baby, talk to your doctor to discuss the risks of taking Alunbrig during pregnancy.
Nogle patienter fik pneumonitis senere i behandlingsforløb med Alunbrig. 
Some patients experienced pneumonitis later in treatment with Alunbrig.
Hypertension Grad 3-hypertension (SYS ≥ 160 mmHg eller DIA ≥ 100 mmHg, medicinsk behandling indiceret, mere end ét antihypertensivum eller mere intensiv behandling end tidligere indiceret anvendt) 
Grade 3 hypertension (SBP ≥ 160 mmHg or DBP ≥ 100 mmHg, medical intervention indicated, more than one anti-hypertensive medicinal product, or more intensive therapy than previously used indicated)
Patienter skal instrueres i at indberette alle synsrelaterede symptomer. 
Patients should be advised to report any visual symptoms.
Det defekte gen danner et unormalt protein, som kaldes en kinase, der stimulerer væksten af kræftcellerne. 
The abnormal gene produces a protein known as a kinase that stimulates the growth of the cancer cells.
Spørg lægen om den form for prævention, der er bedst egnet til dig. 
Ask your doctor about the birth control methods that may be right for you.
Patienter med målbare hjernemetastaser ved baseline 
Patients with measurable brain metastases at baseline
Studie 101: Et åbent fase 1/2-multicenterforsøg med dosiseskalering/udvidelse med patienter med fremskredne maligniteter. 
Study 101: An open-label multicentre phase 1/2 dose escalation/expansion trial in patients with advanced malignancies.
Hvis behandling med Alunbrig afbrydes i 14 dage eller længere tid, af andre årsager end bivirkninger, genoptages behandlingen med 90 mg en gang daglig i 7 dage, inden den øges til den tidligere tolererede dosis. 
If Alunbrig is interrupted for 14 days or longer for reasons other than adverse reactions, treatment should be resumed at 90 mg once daily for 7 days before increasing to the previously tolerated dose.
Hjertefrekvens og blodtryk skal overvåges og måles regelmæssigt. 
Heart rate and blood pressure should be monitored regularly.
Dosisreduktionstrin Første trin 
Dose reduction levels First
Brigatinib er en tyrosinkinase-hæmmer, som er målrettet ALK, c-ros onkogen 1 (ROS1), og insulin-lignende vækstfaktor 1-receptor (IGF-1R). 
Brigatinib is a tyrosine kinase inhibitor that targets ALK, c-ros oncogene 1 (ROS1), and insulin-like growth factor 1 receptor (IGF-1R).
Din læge vil muligvis stoppe behandling med Alunbrig og henvise dig til en øjenlæge. 
Your doctor may stop Alunbrig treatment and refer you to an ophthalmologist.
Der blev set bivirkninger hos dyr ved eksponeringsniveauer, der svarede til kliniske eksponeringsniveauer med mulig relevans for klinisk brug, på følgende områder: mave-tarm-kanalen, knoglemarv, øjne, testes, lever, nyre, knogle og hjerte. 
Adverse reactions seen in animals at exposure levels similar to clinical exposure levels with possible relevance to clinical use were as follows: gastrointestinal system, bone marrow, eyes, testes, liver, kidney, bone, and heart.
Patienter skal overvåges tæt ved samtidig administration af Alunbrig og substrater af disse transportører, som har et smalt terapeutisk indeks (f.eks. digoxin, dabigatran, methotrexat). 
Patients should be closely monitored when Alunbrig is coadministered with substrates of these transporters with a narrow therapeutic index (e.g., digoxin, dabigatran, methotrexate).
Ydre karton: PC: 
Outer Carton: PC:
Fortæl det til lægen, hvis du har problemer med nyrerne eller er i dialyse. 
Tell your doctor if you have kidney problems or you are on dialysis.
Behandlingen med Alunbrig skal seponeres, hvis en patient ikke tolererer en dosis på 60 mg en gang daglig. 
Alunbrig should be permanently discontinued if patient is unable to tolerate the 60 mg once daily dose.
• nedsat antal røde blodlegemer (anæmi) 
• reduced number of red blood cells (anaemia)
• pravastatin, rosuvastatin: lægemidler, der sænker forhøjede kolesterolniveauer 
• pravastatin, rosuvastatin: medicines to lower elevated cholesterol levels
Af disse havde 19 patienter et investigator-bedømt bekræftet objektivt respons (76 %; 95 % CI: 55, 91), og den KM-estimerede mediane varighed af respons blandt de 19 patienter med respons var 26,1 måneder (95 % CI: 7,9; 26,1). 
Of these, 19 patients had an investigator-assessed confirmed objective response (76%; 95% CI: 55, 91) and the KM estimate median duration of response among the 19 responders was 26.1 months (95% CI: 7.9, 26.1).
I ALTA fik 6,4 % af patienterne pulmonale bivirkninger uanset Grad, herunder ILD/pneumonitis, pneumoni og dyspnø, tidligt i behandlingen (inden for 9 dage, median debut: 2 dage), 2,7 % af patienterne fik pulmonale bivirkninger af Grad 3-4 og 1 patient (0,5 %) fik letal pneumoni. 
In ALTA, 6.4% of patients experienced pulmonary adverse reactions of any grade, including ILD/pneumonitis, pneumonia and dyspnoea, early in treatment (within 9 days, median onset: 2 days); 2.7% of patients had Grade 3-4 pulmonary adverse reactions and 1 patient (0.5%) had fatal pneumonia.
Penn Pharmaceutical Services Limited. 
Penn Pharmaceutical Services Limited Units 23-24
Alunbrig indeholder det aktive stof brigatinib, som er type kræftmedicin som kaldes en kinase-hæmmer. 
Alunbrig contains the active substance brigatinib, a type of cancer medicine called a kinase inhibitor.
Fundene omfattede embryo-letalitet, hæmmet fostervækst og knoglevariationer. 
Findings included embryo-lethality, reduced foetal growth, and skeletal variations.
Hos patienterne var plasma-AUC for AP26123 ved steady state < 10 % af brigatinib-eksponeringen. 
In patients, at steady state, the plasma AUC of AP26123 was < 10% of brigatinib exposure.
Almindelig Hukommelsesbesvær Dysgeusi 
Common Memory impairment Dysgeusia
Forekomsten af Grad 3-4-forhøjet CK var 13,6 %. 
The incidence of Grade 3-4 elevations of CPK was 13.6%.
Interstitiel lungesygdom (ILD)/pneumonitis 
Interstitial lung disease (ILD)/pneumonitis
De mest almindelige alvorlige bivirkninger (≥ 2 %), der blev rapporteret hos patienter i behandling med det anbefalede dosisregime for Alunbrig, bortset fra hændelser relateret til tumorprogression, var pneumonitis, pneumoni og dyspnø. 
The most common serious adverse reactions (≥ 2%) reported in patients treated with Alunbrig at the recommended dosing regimen other than events related to neoplasm progression were pneumonitis, pneumonia, and dyspnoea.
Farmakoterapeutisk klassifikation: antineoplastiske stoffer, proteinkinase-hæmmere, ATC-kode: L01XE43 
Pharmacotherapeutic group: antineoplastic agent, protein kinase inhibitors, ATC code: L01XE43
Kvinder i den fødedygtige alder, der er i behandling med Alunbrig, skal undgå at blive gravide. 
Women of childbearing age being treated with Alunbrig should avoid becoming pregnant.
Pædiatrisk population Alunbrigs sikkerhed og virkning hos patienter under 18 år er ikke klarlagt. 
The safety and efficacy of Alunbrig in patients less than 18 years of age have not been established.
Symptomatisk bradykardi 
Symptomatic bradycardia
I forsøg med toksicitet ved gentagne doser blev der set lungeforandringer (skummende alveolære makrofager) hos aber ved ≥ 0,2 gange humant AUC; disse var dog minimale og svarede til dem, der blev rapporteret som baggrundsfund hos naive aber, og der var ingen klinisk dokumentation for respirationsbesvær hos disse aber. 
In repeated dose toxicity studies, lung changes (foamy alveolar macrophages) were noted in monkeys at ≥ 0.2 times the human AUC; however, these were minimal and similar to those reported as background findings in naive monkeys, and there was no clinical evidence of respiratory distress in these monkeys.
reducer til 60 mg en gang daglig seponer behandlingen ikke relevant 
reduce to 60 mg once daily permanently discontinue not applicable
Under forudsætning af, at brigatinib udviser høj opløselighed og høj permeabilitet, forventes hæmning af P-gp og BCRP ikke at medføre klinisk relevante ændringer i den systemiske eksponering af brigatinib. 
Given that brigatinib exhibits high solubility and high permeability, inhibition of P-gp and BCRP is not expected to result in a clinically meaningful change in the systemic exposure of brigatinib.
Baseline-demografi og sygdomskarakteristika i ALTA var en medianalder på 54 år (interval 18 til 82; 23 % 65 og ældre), 67 % var hvide og 31 % var asiater, 57 % var kvinder, 36 % havde ECOG PS 0 og 57 % havde ECOG PS 1, 7 % havde ECOG PS2, 60 % havde aldrig røget, 35 % var tidligere rygere, 5 % var rygere, 98 % havde stadie IV, 97 % havde adenokarcinom og 74 % havde tidligere fået kemoterapi. 
Baseline demographics and disease characteristics in ALTA were median age 54 years old (range 18 to 82; 23% 65 and over), 67% White and 31% Asian, 57% female, 36% ECOG PS 0 and 57% ECOG PS 1, 7% ECOG PS2, 60% never smoker, 35% former smoker, 5% current smoker, 98% Stage IV, 97% adenocarcinoma, and 74% prior chemotherapy.
Brigatinib kan reducere plasmakoncentrationen af samtidigt administrerede lægemidler, som fortrinsvis metaboliseres af CYP3A. 
Brigatinib may reduce plasma levels of coadministered medicinal products that are predominantly metabolised by CYP3A.
Tegn på pneumonitis skal straks udredes hos enhver patient med symptomer på forværret åndedræt. 
Evidence of pneumonitis in any patient with worsening respiratory symptoms should be promptly investigated.
Når du starter behandlingen med Alunbrig, vil lægen muligvis ordinere en pakning til behandlingsopstart. 
At the beginning of your treatment with Alunbrig your doctor may prescribe a treatment initiation pack.
De fleste ekstra-torakale metastaser var i hjernen (69 %, hvoraf 62 % tidligere havde fået strålebehandling af hjernen), 39 % var i knoglerne og 26 % var i leveren. 
The most common sites of extra-thoracic metastasis included 69% brain (of whom 62% had received prior radiation to the brain), 39% bone, and 26% liver.
Tabel 1: Anbefalede reduktionstrin for dosering af Alunbrig Anbefalet dosis 
Table 1: Recommended Alunbrig dose reduction levels Dose
Markedsføringsindehaver skal sikre sig, at enhver sundhedsprofessionel, behandler eller patient, der forventes at udskrive, give eller anvende Alunbrig, har adgang til eller er forsynet med den nedennævnte uddannelsespakke: 
The MAH shall ensure that in each Member State where Alunbrig is marketed, all healthcare professionals and patients/carers who are expected to prescribe and use Alunbrig have access to/are provided with the following educational package:
Der er ikke udført kliniske lægemiddelinteraktionsforsøg med CYP3A-følsomme substrater. 
Clinical drug-drug interaction studies with CYP3A sensitive substrates have not been conducted.
Tabletterne må ikke knuses eller opløses. 
Do not crush or dissolve the tablets.
Den KM-estimerede mediane PFS var 16,3 måneder (95 % CI: 9,2, NE), og sandsynligheden for samlet overlevelse efter 12 måneder var 84,0 % (95 % CI: 62,8; 93,7). 
The KM median PFS was 16.3 months (95% CI: 9.2, NE) and the 12-month probability of overall survival was 84.0% (95% CI: 62.8, 93.7).
Pakning til behandlingsopstart Hver pakning indeholder to primære æsker i en ydre æske. 
Treatment initiation pack Each pack contains two cartons in an outer carton.
Tabletterne skal synkes hele sammen med et glas vand. 
The tablets should be swallowed whole and with water.
Det gives til patienter med en form for lungekræft, som er relateret til en defekt i et gen, der kaldes anaplastisk lymfom-kinase (ALK). 
It is given to patients whose lung cancer is related to an abnormal form of a gene called anaplastic lymphoma kinase (ALK).
Sikkerhedsfarmakologiske forsøg af brigatinib identificerede et potentiale for pulmonale virkninger (ændring i respirationsfrekvens; 1-2 gange human Cmax), kardiovaskulære virkninger (ændret hjertefrekvens og blodtryk, 0,5 gange human Cmax) og nyrerelaterede virkninger (nedsat nyrefunktion, 1-2,5 gange human Cmax), men indikerede ikke et potentiale for QT-forlængelse eller neurofunktionelle virkninger. 
Safety pharmacology studies with brigatinib identified potential for pulmonary effects (altered respiration rate; 1-2 times the human Cmax), cardiovascular effects (altered heart rate and blood pressure; at 0.5 times the human Cmax), and renal effects (reduced renal function; at 1-2.5 times the human Cmax), but did not indicate any potential for QT prolongation or neurofunctional effects.
Ingen patienter fik dosisreduktion som følge af forhøjet ALAT eller ASAT. 
No patients had dose reductions due to elevation of ALT or AST.
• carbamazepin: et lægemiddel til behandling af epilepsi, maniske/depressive episoder og visse smertelidelser 
• carbamazepine: a medicine to treat epilepsy, euphoric/depressive episodes and certain pain conditions
Der opstod også tidlige pulmonale bivirkninger i et dosiseskaleringsforsøg med patienter (N = 137) (Studie 101), herunder tre letale tilfælde (hypoksi, ARDS (acute respiratory distress syndrome) og pneumoni). 
Early pulmonary adverse reactions also occurred in a dose escalation study in patients (N = 137) (Study 101) including three fatal cases (hypoxia, acute respiratory distress syndrome and pneumonia).
I urin og fæces kombineret blev henholdsvis 48 %, 27 % og 9,1 % af den radioaktive dosis udskilt som uændret brigatinib, N-desmethyl-brigatinib (AP26123) og brigatinib-cystein-konjugat. 
In urine and faeces combined, 48%, 27%, and 9.1% of the radioactive dose was excreted as unchanged brigatinib, N-desmethyl brigatinib (AP26123), and brigatinib cysteine conjugate, respectively.
Alunbrig fås som en pakning til behandlingsopstart. 
Alunbrig is available as a treatment initiation pack.
I Studie 101 blev Alunbrigs potentiale for forlængelse af QT-intervallet vurderet hos 123 patienter med fremskredne maligniteter efter doser af 30 mg til 240 mg brigatinib en gang daglig. 
In Study 101, the QT interval prolongation potential of Alunbrig was assessed in 123 patients with advanced malignancies following once daily brigatinib doses of 30 mg to 240 mg.
Alunbrig indeholder lactose 
Alunbrig contains lactose
• rifabutin, rifampicin: lægemidler til behandling af tuberkulose eller visse andre infektioner 
• rifabutin, rifampicin: medicines to treat tuberculosis or certain other infections
Samtidig administration af brigatinib og substrater af P-gp (f.eks. digoxin, dabigatran, colchicin, pravastatin), BCRP (f.eks. methotrexat, rosuvastatin, sulfasalazin), OCT1 (organic cation transporter 1), MATE1 (multidrug and toxin extrusion protein 1) og MATE2K kan øge deres plasmakoncentrationer. 
Coadministration of brigatinib with substrates of P-gp, (e.g., digoxin, dabigatran, colchicine, pravastatin), BCRP (e.g., methotrexate, rosuvastatin, sulfasalazine), organic cation transporter 1 (OCT1), multidrug and toxin extrusion protein 1 (MATE1), and 2K (MATE2K) may increase their plasma concentrations.
Der skal udvises forsigtighed ved administration af Alunbrig i kombination med andre stoffer, der vides at forårsage bradykardi. 
Caution should be exercised when administering Alunbrig in combination with other agents known to cause bradycardia.
Moderate CYP3A-induktorer kan reducere brigatinibs AUC med ca. 50 % baseret på simuleringer fra en fysiologisk baseret farmakokinetisk model. 
Moderate CYP3A inducers may decrease the AUC of brigatinib by approximately 50% based on simulations from a physiologically-based pharmacokinetic model.
Der skal dog udvises forsigtighed, hvis patienten fører motorkøretøj eller betjener maskiner, da der kan forekomme synsforstyrrelser, svimmelhed eller træthed under behandling med Alunbrig. 
However, caution should be exercised when driving or operating machines as patients may experience visual disturbance, dizziness, or fatigue while taking Alunbrig.
Farmakokinetiske populationsanalyser viste, at race og køn ikke har nogen indvirkning på brigatinibs farmakokinetik. 
Population pharmacokinetic analyses showed that race and gender had no impact on the pharmacokinetics of brigatinib.
Hvis samtidig brug af kraftige CYP3A-hæmmere ikke kan undgås, skal dosis af Alunbrig reduceres med ca. 50 % (dvs. fra 180 mg til 90 mg eller fra 90 mg til 60 mg). 
If concomitant use of strong CYP3A inhibitors cannot be avoided, the dose of Alunbrig should be reduced by approximately 50% (i.e. from 180 mg to 90 mg, or from 90 mg to 60 mg).
Brigatinib hæmmede levedygtigheden in vitro og in vivo af celler, der udtrykker mutantformer af EML4-ALK forbundet med resistens over for ALK-hæmmere, herunder G1202R og L1196M. 
Brigatinib inhibited the in vitro and in vivo viability of cells expressing mutant forms of EML4-ALK associated with resistance to ALK inhibitors, including G1202R and L1196M.
Lactosemonohydrat Mikrokrystallinsk cellulose Natriumstivelsesglykolat (type A) Kolloid hydrofob silica Magnesiumstearat 
Lactose monohydrate Microcrystalline cellulose Sodium starch glycolate (type A) Silica colloidal hydrophobic Magnesium stearate
Efter pulmonale bivirkninger af Grad 1-2 blev behandling med Alunbrig enten afbrudt og derefter genopstartet, eller dosis blev reduceret. 
Following Grade 1-2 pulmonary adverse reactions, treatment with Alunbrig was either interrupted and then restarted or the dose was reduced.
Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af forsøg med Alunbrig i alle undergrupper af den pædiatriske population med lungekarcinom (småcellet og ikke-småcellet karcinom) (se pkt. 
The European Medicines Agency has waived the obligation to submit the results of studies with Alunbrig in all subsets of the paediatric population in lung carcinoma (small cell and non-small cell carcinoma) (see section 4.2 for information on paediatric use).
Hos patienter med hjernemetastaser uanset type ved baseline var kontrolraten for intrakraniel sygdom 77,8 % (95 % CI 67,2-86,3) i 90 mg-armen (N = 81) og 85,1 % (95 % CI 75-92,3) i 180 mg-armen (N = 74). 
In patients with any brain metastases at baseline, intracranial disease control rate was 77.8% (95% CI 67.2-86.3) in the 90 mg arm (N = 81) and 85.1% (95% CI 75-92.3) in the 180 mg arm (N=74).
Alunbrig bruges til behandling af voksne med fremskredne stadier af lungekræft af typen ikke-småcellet lungekræft. 
Alunbrig is used to treat adults with advanced stages of a lung cancer called non-small cell lung cancer.
Desuden fik 2,3 % af patienterne i ALTA pneumonitis senere i behandlingen, og 2 patienter fik Grad 3-pneumonitis (se pkt. 
Additionally, 2.3% of patients in ALTA experienced pneumonitis later in treatment, with 2 patients having Grade 3 pneumonitis (see sections 4.2 and 4.4).
Brigatinib er et substrat af P-glykoprotein (P-gp) og brystcancer-resistensprotein (BCRP) in vitro. 
Brigatinib is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in vitro.